Table 7.
Baseline characteristics of patients with or without AVN.
| No AVN (n = 213) | AVN (n = 21) | P value | |
|---|---|---|---|
| Age mean (±SD) | 41.0 (±12.9) | 40.5 (±11.5) | 0.68 |
| Sex F/M (n) | 81/132 | 7/14 | 0.33 |
| Disease (n) | Unknown: 81 Gn/vasculitis: 38 Dm: 25Others: 69 |
Unknown: 11 Gn/vasculitis: 6 Dm: 0 Others: 4 |
0.24 |
| DM, n (%) | 25 (11.7%) | 0 (0%) | 0.09 |
| Vintage, (month) med (min-max) | 45.6 (0–238) | 52.1 (0–231) | 0.59 |
| CNI, n (%) | Tac: 172 (80.7%) CsA: 22 (10.3%) |
Tac: 14 (66.6%) CsA: 5 (23.8%) |
0.09 |
| mTORi, (n) | Eve: 13 (6.1%) Sir: 8 (3.7%) |
Eve: 0 (0%) Sir: 2 (9.5%) |
0.94 |
| Steroid, mg mean (±SD) | 12637.5 (2605.0–79250.5) | 5717.5 (2752.5–56490.0) | 0.002 |
| Steroid duration (month) med (min-max) | 84 (60–325) | 34 (2–201) | <0.001 |
| Antilipidemic n (%) | 16 (7.5%) | 0 (0%) | 0.99 |
| Antiaggregant n (%) | 21 (9.8%) | 1 (4.7%) | 0.04 |
| eGFR mean (±SD) | 75.3 (±24.9) | 68.8 (±23.6) | 0.25 |
| Ca, mmol/L mean (±SD) | 2.38 (±0.15) | 2.38 (±0.17) | 0.92 |
| P, mmol/l mean (±SD) | 1.03 (±0.16) | 1.00 (±0.19) | 0.67 |
| Mg, mmol/L mean (±SD) | 0.85 (±0.15) | 0.90 (±0.10) | 0.78 |
| 25-OH-D, nmol/L mean (±SD) | 79.6 (±28.7) | 90.6 (±25.7) | 0.71 |
| Pre Tx iPTH, ng/L med (min-max) | 573.5 (60.7–2854.2) | 733.1 (141.2–2293.0) | 0.06 |
| 1st year iPTH, ng/L med (min-max) | 67.3 (17.5–2249.2) | 53.2 (14.0–279.9) | 0.16 |
| Hb, g/L mean (±SD) | 127.2 (±21.2) | 120.1 (±16.1) | 0.03 |
| Alb, g/L mean (±SD) | 43.2 (±4.0) | 42.4 (±3.2) | 0.72 |
| LDL, mmol/L mean (±SD) | 2.73 (±0.89) | 2.54 (±0.66) | 0.13 |
| TG, mmol/L mean (±SD) | 1.64 (±0.91) | 1.55 (±0.74) | 0.60 |
| Follow-up (year) med (min-max) | 7.0 (5.0–27.1) | 9.0 (5.0–23.1) | 0.14 |
| Cdx2 CC/CT/TT n (%) | 60.6/31.9/7.5 | 75.3/19.2/5.5 | 0.04 |
| Fok1 AA/AG/GG n (%) | 9.9/41.8/48.3 | 0.0/50.0/50.0 | 0.12 |
| Bsm1 CC/CT/TT n (%) | 37.6/41.3/21.1 | 27.3/59.1/13.6 | 0.03 |
| Apa1 CC/CA/AA n (%) | 23.0/38.0/39.0 | 18.2/59.1/22.7 | 0.02 |
| Taq1 AA/AG/GG n (%) | 40.4/40.4/19.2 | 31.9/54.5/13.6 | 0.09 |